PUFA for Human Health: Diet or Supplementation?

被引:14
作者
Abete, P. [1 ]
Testa, G. [1 ]
Galizia, G. [1 ]
Della-Morte, D. [1 ]
Cacciatore, F. [1 ,2 ]
Rengo, F. [1 ,2 ]
机构
[1] Univ Naples Federico II, Dipartimento Med Clin & Sci Cardiovasc & Immunol, Cattedra Geriatria, I-80131 Naples, Italy
[2] IRCCS, Fdn Salvatore Maugeri, Ist Sci Campoli Telese, Benevento, Italy
关键词
Omega-3 fatty acids; diet; supplementation; triglycerides; POLYUNSATURATED FATTY-ACIDS; CORONARY HEART-DISEASE; FISH-OIL SUPPLEMENTATION; BLOOD-PRESSURE; OMEGA-3-FATTY-ACIDS; LIPOPROTEINS; CONCENTRATE; LIPIDS; CHAIN; TRIGLYCERIDE;
D O I
10.2174/138161209789909665
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Large doses of omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are used to treat several diseases including hypertriglyceridemia in humans. Modest levels of EPA and DHA may be obtained from food, particularly from fatty fish. This review presents the literature examining the differences between omega-3 fatty acid dietary supplementation and prescribed omega-3-acid ethyl esters (P-OM3). Reports published between 1995 and 2007 containing sources, recommended intake, and differences in the various formulations of omega-3 fatty acids were sought in PubMed and the Food and Drug Administration (FDA) Websites. However, lack of head-to-head clinical trials using both P-OM3 and dietary-supplement omega-3 fatty acids is the greatest limitation of this review. Although many kinds of omega-3 fatty acid dietary supplements are available, the efficacy, quality, and safety of these products are questionable because they are beyond any pharmaceutical control. Thus, P-OM3 is the only FDA approved omega-3 fatty acid product which is available in the United States as an adjunct to diet to improve human health.
引用
收藏
页码:4186 / 4190
页数:5
相关论文
共 52 条
[1]   Dietary flaxseed protects against ventricular fibrillation induced by ischemia-reperfusion in normal and hypercholesterolemic rabbits [J].
Ander, BP ;
Weber, AR ;
Rampersad, PP ;
Gilchrist, JSC ;
Pierce, GN ;
Lukas, A .
JOURNAL OF NUTRITION, 2004, 134 (12) :3250-3256
[2]  
[Anonymous], 2006, Med Lett Drugs Ther, V48, P59
[3]   Distribution, interconversion, and dose response of n-3 fatty acids in humans [J].
Arterburn, Linda M. ;
Hall, Eileen Bailey ;
Oken, Harry .
AMERICAN JOURNAL OF CLINICAL NUTRITION, 2006, 83 (06) :1467S-1476S
[4]  
Bays Harold E, 2008, Expert Rev Cardiovasc Ther, V6, P391, DOI 10.1586/14779072.6.3.391
[5]   Safety considerations with omega-3 fatty acid therapy [J].
Bays, Harold E. .
AMERICAN JOURNAL OF CARDIOLOGY, 2007, 99 (6A) :35C-43C
[6]   The effect of an omega-3 ethyl ester concentrate on blood lipid concentrations in patients with hyperlipidaemia [J].
Borthwick, L .
CLINICAL DRUG INVESTIGATION, 1998, 15 (05) :397-404
[7]   Efficiency of conversion of α-linolenic acid to long chain n-3 fatty acids in man [J].
Brenna, JT .
CURRENT OPINION IN CLINICAL NUTRITION AND METABOLIC CARE, 2002, 5 (02) :127-132
[8]   The bioavailability and pharmacodynamics of different concentrations of omega-3 acid ethyl [J].
Bryhn, M. ;
Hansteen, H. ;
Schanche, T. ;
Aakre, S. E. .
PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS, 2006, 75 (01) :19-24
[9]   N-3 polyunsaturated fatty acids in coronary heart disease: A meta-analysis of randomized controlled trials [J].
Bucher, HC ;
Hengstler, P ;
Schindler, C ;
Meier, G .
AMERICAN JOURNAL OF MEDICINE, 2002, 112 (04) :298-304
[10]  
BURR ML, 1989, LANCET, V2, P757